Stock Track | Latigo Biotherapeutics Soars 16.67% in Nasdaq Debut After Upsized $345.6 Million IPO

Stock Track

Aug 07

Latigo Biotherapeutics (LTGO) surged 16.67% in intraday trading on Friday, marking a strong debut on the Nasdaq. The clinical-stage biopharmaceutical company's stock opened well above its initial public offering price, reflecting robust investor demand for its non-opioid pain management pipeline.

The rally was driven by the company's upsized IPO, which priced 19.2 million shares at $18 per share, raising gross proceeds of approximately $345.6 million. The offering was increased from the originally planned 16 million shares, with the price at the top end of the marketed range of $16 to $18. The stock was indicated to open at $20 per share, immediately exceeding the offer price.

Latigo Biotherapeutics focuses on developing non-opioid pain medicines designed to stop pain transmission without the risk of addiction. The company intends to use the proceeds to advance its clinical pipeline, including its lead product candidate, LTG-001, which is being developed to provide fast-acting, opioid-sparing relief for acute pain. The strong debut underscores market confidence in the company's therapeutic approach amid a broader push for alternatives to opioid-based treatments.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1185286978"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1185286978\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1185286978?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-07 23:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1185286978","market":"nz","top_or_hot":-1,"title":"Stock Track | Latigo Biotherapeutics Soars 16.67% in Nasdaq Debut After Upsized $345.6 Million IPO","media":"Stock Track","content":"<p>Latigo Biotherapeutics (LTGO) surged 16.67% in intraday trading on Friday, marking a strong debut on the Nasdaq. The clinical-stage biopharmaceutical company's stock opened well above its initial public offering price, reflecting robust investor demand for its non-opioid pain management pipeline.</p><p>The rally was driven by the company's upsized IPO, which priced 19.2 million shares at $18 per share, raising gross proceeds of approximately $345.6 million. The offering was increased from the originally planned 16 million shares, with the price at the top end of the marketed range of $16 to $18. The stock was indicated to open at $20 per share, immediately exceeding the offer price.</p><p>Latigo Biotherapeutics focuses on developing non-opioid pain medicines designed to stop pain transmission without the risk of addiction. The company intends to use the proceeds to advance its clinical pipeline, including its lead product candidate, LTG-001, which is being developed to provide fast-acting, opioid-sparing relief for acute pain. The strong debut underscores market confidence in the company's therapeutic approach amid a broader push for alternatives to opioid-based treatments.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Latigo Biotherapeutics Soars 16.67% in Nasdaq Debut After Upsized $345.6 Million IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Latigo Biotherapeutics Soars 16.67% in Nasdaq Debut After Upsized $345.6 Million IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-08-07 23:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Latigo Biotherapeutics (LTGO) surged 16.67% in intraday trading on Friday, marking a strong debut on the Nasdaq. The clinical-stage biopharmaceutical company's stock opened well above its initial public offering price, reflecting robust investor demand for its non-opioid pain management pipeline.</p><p>The rally was driven by the company's upsized IPO, which priced 19.2 million shares at $18 per share, raising gross proceeds of approximately $345.6 million. The offering was increased from the originally planned 16 million shares, with the price at the top end of the marketed range of $16 to $18. The stock was indicated to open at $20 per share, immediately exceeding the offer price.</p><p>Latigo Biotherapeutics focuses on developing non-opioid pain medicines designed to stop pain transmission without the risk of addiction. The company intends to use the proceeds to advance its clinical pipeline, including its lead product candidate, LTG-001, which is being developed to provide fast-acting, opioid-sparing relief for acute pain. The strong debut underscores market confidence in the company's therapeutic approach amid a broader push for alternatives to opioid-based treatments.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LTGO","symbol_name":"Latigo Biotherapeutics Inc","start_time":0,"source_url":"","article_id":"1185286978","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1185286978","pubTimestamp":1786117348,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Latigo Biotherapeutics (LTGO) surged 16.67% in intraday trading on Friday, marking a strong debut on the Nasdaq. The clinical-stage biopharmaceutical company's stock opened well above its initial...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LTGO":"Latigo Biotherapeutics Inc"},"translate_title":"股票追踪 | Latigo Biotherapeutics 在纳斯达克首次公开募股 3.456 亿美元后飙升 16.67%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LTGO":1},"content_text":"Latigo Biotherapeutics (LTGO) surged 16.67% in intraday trading on Friday, marking a strong debut on the Nasdaq. The clinical-stage biopharmaceutical company's stock opened well above its initial public offering price, reflecting robust investor demand for its non-opioid pain management pipeline.The rally was driven by the company's upsized IPO, which priced 19.2 million shares at $18 per share, raising gross proceeds of approximately $345.6 million. The offering was increased from the originally planned 16 million shares, with the price at the top end of the marketed range of $16 to $18. The stock was indicated to open at $20 per share, immediately exceeding the offer price.Latigo Biotherapeutics focuses on developing non-opioid pain medicines designed to stop pain transmission without the risk of addiction. The company intends to use the proceeds to advance its clinical pipeline, including its lead product candidate, LTG-001, which is being developed to provide fast-acting, opioid-sparing relief for acute pain. The strong debut underscores market confidence in the company's therapeutic approach amid a broader push for alternatives to opioid-based treatments.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}